New approach to managing genital warts

Catharine C. Lopaschuk MD CCFP MHSc

Abstract

Objective To summarize and determine the appropriate use for the new and old management tools for genital warts.

Sources of information The following databases were searched: MEDLINE, PubMed, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, ACP Journal Club, and Trip. The bibliographies of retrieved papers were also reviewed. Clinical trials, qualitative review articles, consensus reports, and clinical practice guidelines were retrieved.

Main message Symptomatic warts are prevalent in at least 1% of the population between the ages of 15 and 49, with estimates of up to 50% of the population being infected with human papillomavirus at some point in their lifetime. Imiquimod and podophyllotoxin are 2 new treatments for external genital warts that are less painful and can be applied by patients at home. In addition, the quadrivalent human papillomavirus vaccine has been shown to be efficacious in preventing genital warts and cervical cancer. There is still a role for the older treatment methods in certain situations, such as intravaginal, urethral, anal, or recalcitrant warts; or for pregnant patients.

Conclusion The new treatments of external genital warts can reduce the pain of treatment and the number of office visits. Other treatment methods are still useful in certain situations.

Case introduction A 24-year-old woman presents to the office with a 3-month history of tender, itchy “bumps” on her vulva. She is a competitive cyclist and finds that biking irritates the bumps and causes them to bleed at times. She is not currently sexually active, but has had 4 male sexual partners in the past, with the most recent relationship ending 6 months ago. On examination you find multiple papillomatous lesions on her outer labia that are consistent with the appearance of warts. As you reach for the podophyllin, you remember hearing about some new topical treatments for genital warts that are more convenient and less toxic. You also wonder if you should be discussing the human papillomavirus (HPV) vaccine with your patient.

Sources of information The databases MEDLINE, PubMed, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, ACP Journal Club, and Trip were searched up to March 2011. Searches were conducted for each treatment individually and were limited to English-language articles. The search terms used were warts or condyloma acuminata or papilloma virus and venereal or genital or vaginal and the specific treatment. The bibliographies of retrieved papers were also scanned for relevant articles. Excluded were articles examining cervical neoplasia and studies done in subjects who were immunocompromised, HIV-positive, or homosexual men.

Seventy-seven relevant articles were retrieved and their abstracts were assessed for inclusion in this evidence-based review, with preference given to high-quality systematic reviews from the Cochrane Collaboration. Of the retrieved papers, 49 were read and 30 were included in this review.

The recommendations and the level of evidence were graded using the Canadian Task Force on Preventive Health Care system (Table 1).

Main message Genital warts are a common cause of morbidity. Symptomatic warts are prevalent in at least 1% of the population between the ages of 15 and 49, with...
warts will spontaneously resolve in 9 to 12 months, with HPV at some point in their lifetime. New treatments have become available in the past decade that have pushed some of the old treatments, such as podophyllin, into lesser favour. This review presents the new approaches to the treatment and management of genital warts, while including possible roles for some of the old treatments (Table 2 and Figures 1 and 2).

Visible genital warts can be psychologically and physically distressing for patients. While warts are often asymptomatic, at other times they can cause pain, itching, burning, irritation against clothing, and occasionally bleeding. They can also cause pain and bleeding during sexual activity.

Treatment of benign, symptomatic genital warts is aimed at alleviation of physical symptoms and cosmetic improvement. From 40% to 60% of untreated warts will spontaneously resolve in 9 to 12 months, but many patients are psychologically distressed by the presence of warts and require intervention to eradicate them (Box 1).

Genital warts are caused by several strains of HPV and are spread by skin-to-skin contact during sexual activity. They are, therefore, considered a sexually transmitted infection (STI). A number of different treatments are available. Some of these treatments can be self-applied by the patients, while others require treatment by a nurse or physician. In this article, I have included older treatments (eg, podophyllin) that might now be relegated to use only in difficult cases, as they are familiar to many general practitioners who have been in practice for decades. It might be useful for them to know where these treatments now stand. I have also included some new, less-used treatments (interferon, sinecatechins) because readers might have heard about them and wondered about their use.

The diagnosis of genital warts is made by visual inspection for the appearance of lesions consistent with warts. They can appear as papillomatous plaques or flat lesions, and can be singular or multiple, or can coalesce into condylomata acuminata. They can vary from flesh-coloured to white, pink, or brown. The locations involved in women can be the cervix, vagina, vulva, urethral meatus, and perianal region. In men, the scrotum, penis shaft, corona and under the foreskin, and perianal region can be involved.

The differential diagnosis includes sebaceous glands, seborrheic keratoses, molluscum contagiosum, psoriasis, teratogenicity, but are still useful in difficult cases because of lack of evidence, more severe side effects, or contraindicated, or are not tolerated by the patient, and are not financially feasible (eg, periurethral warts), try a not-generally-recommended therapy. They are not usually recommended because of lack of evidence, more severe side effects, or teratogenicity, but are still useful in difficult cases. If no available options for treatment have failed, then refer the patient to a local sexually transmitted infection clinic, gynecologist, dermatologist, or urologist for treatment.

Table 1. Grades of recommendations and levels of evidence from the Canadian Task Force on Preventive Health Care

<table>
<thead>
<tr>
<th>GRADE OR LEVEL</th>
<th>RECOMMENDATION OR EVIDENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>There is good evidence to recommend the clinical preventive action</td>
</tr>
<tr>
<td>B</td>
<td>There is fair evidence to recommend the clinical preventive action</td>
</tr>
<tr>
<td>C</td>
<td>The existing evidence is conflicting and does not allow a recommendation for or against the use of the clinical preventive action; however, other factors might influence decision making</td>
</tr>
<tr>
<td>D</td>
<td>There is fair evidence to recommend against the clinical preventive action</td>
</tr>
<tr>
<td>E</td>
<td>There is good evidence to recommend against the clinical preventive action</td>
</tr>
<tr>
<td>F</td>
<td>There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors might influence decision making</td>
</tr>
<tr>
<td>I</td>
<td>At least 1 properly conducted randomized controlled trial, systematic review, or meta-analysis</td>
</tr>
<tr>
<td>II</td>
<td>Other comparison trials, non-randomized studies, cohort studies, case-control studies, or epidemiologic studies, and preferably more than 1 study</td>
</tr>
<tr>
<td>III</td>
<td>Expert opinion or consensus statements</td>
</tr>
</tbody>
</table>

Adapted from the Canadian Task Force on Preventive Health Care.

Box 1. Getting started

- Discuss the treatment options with the patient, including observation, and consider the location of the warts, extent of involvement for painful treatments (cryotherapy or trichloroacetic acid), and the possibility of pregnancy
- Order a pregnancy test and discuss contraception with fertile women if treating with imiquimod, podophyllotoxin, or podophyllin
- Start treatment with a first-choice therapy and continue for the recommended duration
- Reassess at the end of the treatment and repeat the treatment if lesions are not cleared, or if new ones have appeared
- If lesions do not seem to be responding to treatment after 2 or 3 cycles, try an alternate first-choice therapy. If there is a response to treatment, you can keep going with the same therapy, repeating cycles of treatment as needed
- Continue in this manner until you find the treatment that works for this patient. Choose a second-choice therapy if you fail to find a suitable first-choice therapy
- In situations in which the first-choice therapies have failed, are contraindicated, or are not tolerated by the patient, and the second-choice therapies are not available, or are not feasible (eg, periurethral warts), try a not-generally-recommended therapy. They are not usually recommended because of lack of evidence, more severe side effects, or teratogenicity, but are still useful in difficult cases
- If all available options for treatment have failed, then refer the patient to a local sexually transmitted infection clinic, gynecologist, dermatologist, or urologist for treatment
lichens, lichen planus, melanocytic nevi, fibroepitheliomas, neoplasia, and condylomata lata (syphilis). Occasionally, a biopsy is indicated to confirm the diagnosis and rule out malignancy. Testing for acetowhitening with a 3% to 5% acetic acid solution (household vinegar) is not recommended because it is considered too nonspecific to serve as a diagnostic tool. A positive acetowhitening test can be an indication for further evaluation, including a biopsy.

### Table 2: Preferred and alternative treatment options

<table>
<thead>
<tr>
<th>Treatment, Level of Evidence, and Grade of Recommendation</th>
<th>Clearance, %</th>
<th>Recurrence, %</th>
<th>Application Regimen</th>
<th>Adverse Effects</th>
<th>Safe For Intravaginal or Intracutaneous Use</th>
<th>Safe For Use in Pregnancy or Lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient-applied treatments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imiquimod 5% cream(^a)* (grade B, level II)(^*)</td>
<td>51</td>
<td>22-63</td>
<td>Apply with finger 3 nights/wk for 16 wk Wash off in the morning</td>
<td>Localized erythema, burning, inflammation; rarely, hypopigmentation Might weaken latex condoms and diaphragms</td>
<td>No</td>
<td>No; safety unknown</td>
</tr>
<tr>
<td>Podophyllotoxin 0.5% solution or gel(^d) (grade B, level II)(^*)</td>
<td>56</td>
<td>2-90</td>
<td>Apply with swab or finger 2 times/d for 3 d, then 4 d off, for up to 4 cycles. Limit of 10 cm(^2)/d of skin surface or 0.5 mL/d</td>
<td>Localized burning, pain, itching, erosion, inflammation</td>
<td>No</td>
<td>No; it is an extract of podophyllin, which is teratogenic</td>
</tr>
<tr>
<td><strong>Provider-applied treatments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryotherapy(^5-12) (grade B, level I)(^*)</td>
<td>27-88</td>
<td>25-55</td>
<td>Once per wk with cotton swab, spray, or cryoprobe (not in the vagina)</td>
<td>Localized pain, inflammation, scarring Risk of vaginal perforation if using cryoprobe</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>TCA(^10,11,13) (grade B, level II)(^*)</td>
<td>63-70</td>
<td>35</td>
<td>Once per wk with cotton swab or toothpick</td>
<td>Localized pain and ulceration Can neutralize with sodium bicarbonate solution</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Excision(^14) (grade B, level II)(^*)</td>
<td>35-72</td>
<td>19-79</td>
<td>Local anesthesia then excision of lesions</td>
<td>Pain, bleeding, infection</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Electrocautery(^14) (grade B, level II)(^*)</td>
<td>61-94</td>
<td>22</td>
<td>Local anesthesia then destruction of lesions with cautery tools</td>
<td>Pain, bleeding, infection Operator should wear a virus-filtering mask</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Alternative treatments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Podophyllin 25% in tincture of benzoin(^14-16) (grade C, level II)(^*)</td>
<td>23-72</td>
<td>23-65</td>
<td>Once per wk with cotton swab or toothpick Limit 10 cm(^2)/d of skin surface or 0.5 mL per treatment</td>
<td>Localized burning, pain, itching, erosion, inflammation Limit &lt; 2 cm(^2) of skin surface</td>
<td>No; is teratogenic</td>
<td></td>
</tr>
<tr>
<td>Sinecatechins (green tea extract) 15% ointment(^11,18) (grade B, level II; 2 trials)(^*)</td>
<td>57</td>
<td>6.5</td>
<td>Apply 3 times/d for up to 16 wk</td>
<td>Localized erythema, burning, pain, rash, ulceration</td>
<td>No; not studied</td>
<td>No; not studied</td>
</tr>
<tr>
<td>Fluorouracil 1% gel or 5% cream(^13,30) (grade C, level II)(^*)</td>
<td>80-90</td>
<td>No data</td>
<td>Insert applicatorful into vagina 3 nights/wk</td>
<td>Erythema, erosion, edema</td>
<td>Yes</td>
<td>No; is teratogenic</td>
</tr>
<tr>
<td>Interferon(^21) (grade C, level II)(^*)</td>
<td>44.4</td>
<td>21.4</td>
<td>One applicatorful in vagina twice daily for 5 d/wk for 4 wk</td>
<td>Headache, tenderness, transient fever</td>
<td>Yes</td>
<td>No; not studied</td>
</tr>
<tr>
<td>Observation(^*14)</td>
<td>40-60</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
</tbody>
</table>

TCA—trichloroacetic acid.

*First-choice therapy.

*Second-choice therapy.

*Not-generally-recommended therapy.
be useful.\(^4\) Human papillomavirus types 16 and 18 cause more than 70% of cases of invasive cervical cancer.\(^{24}\) More than 90% of cases of benign disease (genital warts) are caused by types 6 and 11.\(^{15}\)

Transmission of HPV to a neonate can result in laryngeal papillomatosis in the newborn. As this is a rare, non-malignant condition, and it is unclear whether the newborn becomes infected during birth or post partum, cesarean section is not recommended for prevention (grade C, level II).\(^4\)

There is a consensus of expert opinion that attempts should be made to reduce the HPV load in pregnant women by treating genital warts before vaginal delivery, although there is no evidence that such treatment reduces viral load (levels I to III).\(^4\) There is a lack of evidence that treatment of visible warts

---

**Figure 1. Management of genital warts in nonpregnant patients**

![Diagram of management of genital warts](image)

- **External genital warts**
  - Refer patients with cervical warts for colposcopy
  - Pregnant
    - Symptomatic: External skin (cutaneous)
      - Patient-applied therapy: Imiquimod or podophyllotoxin Limit 10 cm\(^2\)
      - Cryotherapy TCA Both limited by patient’s pain tolerance
      - Excision Cautery Laser
      - Sinecatechins
      - Fluorouracil Interferon Podophyllin Limit 2 cm\(^2\)
    - Asymptomatic: Vaginal, urethral, or anal
      - Observe
      - Imiquimod or podophyllotoxin
      - Observe

- **Not pregnant**
  - Symptomatic: External skin (cutaneous)
    - Provider-applied therapy
    - Observe
    - Cryotherapy TCA Both limited by patient’s pain tolerance
    - Excision Cautery Laser
    - Sinecatechins
    - Fluorouracil Interferon Podophyllin Limit 2 cm\(^2\)
  - Asymptomatic
    - Observe

**First-choice therapies**
- Cryotherapy
- TCA

**Second-choice therapies for use if above choices fail or are not tolerated**
- Imiquimod or podophyllotoxin Limit 10 cm\(^2\)
- Excision Cautery Laser
- Sinecatechins
- Fluorouracil Interferon Podophyllin Limit 2 cm\(^2\)

**Not-generally-recommended therapies for use if above treatments are not tolerated, are not available, or have failed**
- Imiquimod or podophyllotoxin
- Observe
- Imiquimod or podophyllotoxin
- Observe

---

**Figure 2. Management of cervical warts**

- Refer patients with cervical warts for colposcopy
  - External skin (cutaneous)
    - Patient-applied therapy: Imiquimod or podophyllotoxin Limit 10 cm\(^2\)
    - Cryotherapy TCA Both limited by patient’s pain tolerance
    - Excision Cautery Laser
    - Sinecatechins
    - Fluorouracil Interferon Podophyllin Limit 2 cm\(^2\)
  - Vaginal
    - Observe
    - Cryotherapy TCA Both limited by patient’s pain tolerance
    - Excision Cautery Laser
    - Sinecatechins
    - Fluorouracil Interferon Podophyllin Limit 2 cm\(^2\)

**Contraception advice**
- Contraception advice
- Safer sex using condoms

**Screening and referral if needed**
- STI screen, and referral if needed
- Contraception advice
- Safer sex using condoms
- Follow up 2-3 months after treatment to assess for new lesions or recurrences
- Gynecology, dermatology, urology, or STI clinic referral as needed

---

**HPV—human papillomavirus, STI—sexually transmitted infection, TCA—trichloroacetic acid.**
eradicates the HPV infection or prevents transmission of the virus.4,25

Other management and prevention
Quadrivalent HPV vaccine protects against HPV types 6, 11, 16, and 18, the strains that most commonly cause benign warts and cervical cancer. Initial studies in women showed that it is 90% to 100% efficacious in preventing genital warts.26 After the introduction of a vaccination program in 2007, 4-year follow-up of young, sexually active women in Australia showed a marked decline in the prevalence of genital warts from 11.7% to 4.8% by 2009, and an ongoing, slower decline since then. There has been an associated, but less dramatic, decline in the incidence of warts in heterosexual men as well, presumably through reduced exposure to the virus as more of their partners were vaccinated.27,28

At this time, Canada has approved the quadrivalent HPV vaccine for women aged 9 to 26 years. It is recommended that women who present with genital warts and who have not yet been vaccinated should be offered the vaccine (3 doses at 0, 2, and 6 months). While it does not clear current HPV infection, it might help prevent reinfection with other strains (in particular the higher risk types 16 or 18). There is grade A, level I evidence that the quadrivalent HPV vaccine prevents cervical cancer3,4 (not addressed in this paper) and grade B, level I evidence that it prevents genital warts.23,27

The quadrivalent HPV vaccine has an increased cost utility; it reduces the cost burden, as it prevents both genital warts and cervical cancer, compared with a vaccination for cervical cancer alone.3

Other than administering the quadrivalent HPV vaccine, the following recommendations are made to prevent and manage genital warts:

- All women should have Papanicolaou smears to screen for co-infection with oncogenous strains.
- Women should be screened for other STIs according to STI guidelines. Screening partners for warts is not indicated.4 Genital warts do not need to be treated unless they are symptomatic.
- Anoscopy should be performed to confirm the diagnosis of symptomatic (itching, painful, bleeding) intra-anal warts. Asymptomatic warts can be observed, so a diagnosis is unnecessary. They can occur without a history of anal-receptive intercourse.
- Contraception might need to be discussed and prescribed, particularly if using a wart treatment that is contraindicated in pregnancy. Keep in mind that imiquimod might weaken latex barrier devices such as condoms and diaphragms.
- Condoms do offer protection, although incomplete protection, against transmission of HPV (grade B, level II).29,30
- Follow-up at 2 to 3 months after achieving wart clearance is recommended, to check for recurrence or new lesions.
- Patients with recalcitrant (difficult to treat), symptomatic warts should be referred to local STI clinics, gynecologists, dermatologists, or urologists.

Case resolution
Your diagnosis is genital warts. You do a Pap smear and screen for gonorrhea and chlamydia. You advise the patient that condoms might help to prevent transmission. After discussion of treatment versus observation, she decides that she would like to treat the warts because they are bothering her. You prescribe her a contraceptive before initiating treatment, and you also arrange for her to receive the quadrivalent HPV vaccine. You prescribe imiquimod 5% cream, to be applied at home 3 nights a week for 16 weeks. When you see her again, 2 months after she finishes the treatment, there are no longer any visible warts.
Limitations
This review was limited by the evidence available, in English, at the time of writing. Systematic reviews were available for 5 of the therapies, but even so, some of the studies used in the reviews were not of high quality (eg, studies of fluorouracil). Other therapies have a lot more research behind them (eg, imiquimod). Information on safety in pregnancy is lacking for imiquimod, interferon, and sinecatechins. And some research results are still pending (eg, for the HPV vaccine). This topic would be worth reviewing again in 4 years.

Conclusion
When, and how, to treat genital warts is a decision that the patient and clinician should make together. The choice of treatment should consider the severity of the symptoms—both psychological and physical—and weigh that against the adverse effects of the treatment. The final decision might depend on the extent of the warts and the tolerance the patient has for painful treatments, or the time that the patient is willing to invest in repeated treatments. The advent of patient-applied therapies reduces the burden of repeated visits to a clinic.

Dr Lopaschuk is Assistant Clinical Professor in the Department of Family Medicine of the Faculty of Medicine and Dentistry at the University of Alberta in Edmonton.

Competing interests
None declared

Correspondence
Dr Catharine C. Lopaschuk, Department of Family Medicine, University of Alberta, 265 College Plaza, Edmonton, AB T6G 2C8, e-mail c.lopaschuk@shaw.ca

References

Clinical Review | New approach to managing genital warts